Related Experiment Video
Updated: Jul 11, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
MAGED2: a novel p53-dissociator
Chris Papageorgio1, Rainer Brachmann, Jue Zeng
1Hematology and Medical Oncology, Ellis Fischel Cancer Center, University of Missouri-Columbia, Columbia, MO 65203, USA. papageorgioc@health.missouri.edu
Abstract:
The tumor suppressor protein p53 is a transcription factor that is frequently mutated in human cancers. In response to DNA damage, unmutated or wild-type (wt) p53 protein is stabilized and activated by post-transcriptional modifications that enable it to induce either apoptosis or cell cycle arrest. Using a yeast p53-dissociator assay, we identified MAGED2 as a potential negative regulator of wt p53 activity. Subsequently, using co-immunoprecipitation and reporter gene assays in human cultured cells that are often adopted for functional analysis of p53 we demonstrated that MAGED2 interacted physically with p53 and modified its activity. Finally, we were able to illustrate expression of both p53 and MAGED2 within the same subcellular compartment, i.e. either nucleus or cytoplasm, in 2,682 human cancer tissue specimens using a common cancer tissue microarray and antibodies against MAGED2 and p53. The present results implicate MAGED2, a novel protein, as a p53-dissociator.
Insights
Researchers identified MAGED2 as a novel protein that negatively regulates wild-type p53 activity. MAGED2 interacts with p53, affecting its function in cancer cells and tissues.
Area of Science:
- Molecular Biology
- Cancer Research
- Protein Interactions
Background:
- The tumor suppressor protein p53 is a critical transcription factor frequently mutated in human cancers.
- Wild-type p53 (wt p53) is activated by post-transcriptional modifications upon DNA damage, inducing apoptosis or cell cycle arrest.
Purpose of the Study:
- To identify novel regulators of wild-type p53 activity.
- To investigate the role of MAGED2 in modulating p53 function.
Main Methods:
- Yeast p53-dissociator assay to identify potential regulators.
- Co-immunoprecipitation and reporter gene assays in human cultured cells.
- Analysis of p53 and MAGED2 co-expression in human cancer tissue microarrays.
Main Results:
- MAGED2 was identified as a potential negative regulator of wt p53.
- MAGED2 physically interacts with p53 and modifies its activity in human cells.
- Co-expression of p53 and MAGED2 was observed in the nucleus and cytoplasm of 2,682 human cancer specimens.
Conclusions:
- MAGED2 acts as a novel p53-dissociator, negatively regulating wt p53 activity.
- The interaction between MAGED2 and p53 has implications for cancer biology.
- MAGED2 represents a potential target for cancer therapy.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

